Why Tilray Earnings Are Still Hazy for Investors

By Chris Lange Updated Jan 30, 8:46PM EST · Published May 15, 10:40AM EDT

Follow 24/7 Wall St. on Google

This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.

Why Tilray Earnings Are Still Hazy for Investors — © Thinkstock

When cannabis company Tilray Inc. (NASDAQ: TLRY) reported its most recent quarterly results after the markets closed on Tuesday, it said that it had a net loss of $0.27 per share on $23.0 million in revenue. Consensus estimates had called for a net loss of $0.27 per share and $20.16 million in revenue for the first quarter.

During the quarter, revenue increased 195% year over year, driven by the legalization of Canadian adult-use in 2018, the addition of hemp food sales from the Manitoba Harvest acquisition during the quarter, and strong growth in international medical markets.

Total kilogram equivalents sold increased over twofold to 3,012 kilograms from 1,299 kilograms in the prior year period. Average net selling price per gram decreased to $5.60 from $5.94 in the prior-year period. The average net selling price excluding excise taxes was $5.28 (C$7.02) per gram for the first quarter of 2019.

The company did not issue any guidance in the report. The consensus estimates call for a net loss of $0.24 per share and $40.89 million in revenue for the second quarter.

[nativounit]

Brendan Kennedy, Tilray’s president and CEO, commented:

We are pleased with our first quarter results and the ongoing, substantial progress our team has made to position Tilray as a global leader in the cannabis industry. We have made significant progress integrating our recent acquisitions of Manitoba Harvest and Natura Naturals, accelerating our entry into the United States hemp and CBD markets, and increasing our production and manufacturing capacity in North America and Europe. As we expand our operations around the world, we remain focused on making disciplined investments to maximize the multiple paths to value creation we are aggressively pursuing for our visionary investors.

Shares of Tilray traded down more than 2% at $47.44 Wednesday morning, in a 52-week range of $20.10 to $300.00. The consensus price target is $106.00.

[recirclink id=547584]
[wallst_email_signup]

About the Author Chris Lange →

Chris Lange is a writer for 24/7 Wall St., based in Houston. He has covered financial markets over the past decade with an emphasis on healthcare, tech, and IPOs. During this time, he has published thousands of articles with insightful analysis across these complex fields. Currently, Lange's focus is on military and geopolitical topics.

Lange's work has been quoted or mentioned in Forbes, The New York Times, Business Insider, USA Today, MSN, Yahoo, The Verge, Vice, The Intelligencer, Quartz, Nasdaq, The Motley Fool, Fox Business, International Business Times, The Street, Seeking Alpha, Barron’s, Benzinga, and many other major publications.

A graduate of Southwestern University in Georgetown, Texas, Lange majored in business with a particular focus on investments. He has previous experience in the banking industry and startups.